Trials / Recruiting
RecruitingNCT07110571
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab Injection | Adebrelimab injection. |
| DRUG | SHR-A1811 for Injection | SHR-A1811 for injection. |
| DRUG | SHR-A1904 for Injection | SHR-A1904 for injection. |
| DRUG | SHR-8068 Injection | SHR-8068 injection. |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2026-08-01
- Completion
- 2027-05-01
- First posted
- 2025-08-07
- Last updated
- 2026-01-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07110571. Inclusion in this directory is not an endorsement.